Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine to prevent cyclosporine-associated acute kidney injury after bone marrow transplantation
IRCT201306031030N14Phase 3Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute kidney failure (AKF) and 1 more, sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Primary endpoint: Incidence of acute kidney injury. Started Jul 2012; status: completed.
02
Drugs
acetylcysteine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute kidney failure (AKF)drug-induced nephropathy (DIN)
Beyond the preview
Go deeper on IRCT201306031030N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201306031030N14.